Nuvalent | Investor Presentation Deck | 39 slides · page 32 of 39
The slide outlines the study design for NVL-655, including dose levels for Phase 1 and specific inclusion criteria for Phase 2 cohorts (2a-2d).
Pitch deck · appendix_methodology · plan_implementation · balanced density
Slide locked Sign in to view
Slide schematic 4/4
callout 1/1 disclaimer 1/1 table 1/1 title 1/1
Components 4
primary disclaimer data headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.